Literature DB >> 29956743

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review).

Xiaoting Sun1, Qi Li1.   

Abstract

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29956743     DOI: 10.3892/ijmm.2018.3744

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  15 in total

1.  Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer.

Authors:  Yoshihiro Watanabe; Yorihisa Imanishi; Hiroyuki Ozawa; Koji Sakamoto; Ryoichi Fujii; Seiji Shigetomi; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Mariko Sekimizu; Fumihiro Ito; Yuichi Ikari; Shin Saito; Kaori Kameyama; Kaoru Ogawa
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

2.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 3.  Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy.

Authors:  Qiushi Wang; Rebecca J Morris; Ann M Bode; Tianshun Zhang
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

Review 4.  Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

Authors:  Irati Beltrán Hernández; Jannes Z Kromhout; Erik Teske; Wim E Hennink; Sebastiaan A van Nimwegen; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

5.  Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.

Authors:  Yun Wang; Long Cui; Peter Georgiev; Latika Singh; Yanyan Zheng; Ying Yu; Jeff Grein; Chunsheng Zhang; Eric S Muise; David L Sloman; Heidi Ferguson; Hongshi Yu; Cristina St Pierre; Pranal J Dakle; Vincenzo Pucci; James Baker; Andrey Loboda; Doug Linn; Christopher Brynczka; Doug Wilson; Brian B Haines; Brian Long; Richard Wnek; Svetlana Sadekova; Michael Rosenzweig; Andrew Haidle; Yongxin Han; Sheila H Ranganath
Journal:  Oncoimmunology       Date:  2021-03-18       Impact factor: 8.110

Review 6.  Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression.

Authors:  Jinhua Wang; Dangdang Li; Bo Zhao; Juhyok Kim; Guangchao Sui; Jinming Shi
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 7.  EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.

Authors:  Madison N Sluter; Ruida Hou; Lexiao Li; Nelufar Yasmen; Ying Yu; Jiawang Liu; Jianxiong Jiang
Journal:  J Med Chem       Date:  2021-08-05       Impact factor: 8.039

Review 8.  The constitutive activity of the viral-encoded G protein-coupled receptor US28 supports a complex signalling network contributing to cancer development.

Authors:  Carole A Daly; Martine J Smit; Bianca Plouffe
Journal:  Biochem Soc Trans       Date:  2020-08-28       Impact factor: 5.407

9.  Induction of p53-Dependent Apoptosis by Prostaglandin A2.

Authors:  Su-Been Lee; Sangsun Lee; Ji-Young Park; Sun-Young Lee; Ho-Shik Kim
Journal:  Biomolecules       Date:  2020-03-24

10.  The role of EP-2 receptor expression in cervical intraepithelial neoplasia.

Authors:  Elisa Schmoeckel; Patricia Fraungruber; Christina Kuhn; Udo Jeschke; Sven Mahner; Theresa Maria Kolben; Thomas Kolben; Theresa Vilsmaier; Anna Hester; Helene Hildegard Heidegger
Journal:  Histochem Cell Biol       Date:  2020-08-26       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.